Ilda F.
- Country
- Portugal
- Department
- Oncology service
Research Overview
- Phase 3 Multicenter Randomized Study of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in High-Risk HER2-Positive Breast Cancer with Residual Disease
- Phase 3 Randomized Study of Trastuzumab Deruxtecan vs. Ramucirumab and Paclitaxel in HER2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase 3 Study of Trastuzumab Deruxtecan with Chemotherapy ± Pembrolizumab vs. Chemotherapy with Trastuzumab ± Pembrolizumab in HER2-Positive Gastric/GEJ Cancer
Data & Insights
Has run more than one trial at 49 of 215 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in treating high-risk HER2-positive breast cancer, with particular emphasis on post-neoadjuvant therapeutic approaches. Their research explores advanced treatment options for patients with residual disease following initial therapy.
- HER2-positive breast cancer management
- Post-neoadjuvant therapy optimization
- Targeted antibody-drug conjugates
Their work focuses on evaluating novel therapeutic strategies for improving patient outcomes in high-risk breast cancer scenarios.
Gastrointestinal Oncology
The investigator conducts research in advanced gastric cancer and gastro-esophageal junction adenocarcinoma, particularly in HER2-positive cases. Their work encompasses treatment strategies for patients who have progressed after initial targeted therapy.
- Gastric cancer treatment
- GEJ adenocarcinoma management
- HER2-targeted therapies
The research extends to evaluating survival outcomes in patients with metastatic gastric cancer using innovative therapeutic approaches.
Targeted Therapy Development
This investigator specializes in the application of targeted antibody-drug conjugates across multiple cancer types. Their expertise includes evaluating novel therapeutic agents for both breast and gastric cancers.
- Antibody-drug conjugate applications
- Treatment resistance management
- Advanced therapeutic strategies
Their research encompasses comparative analyses of different targeted therapies in HER2-positive cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.